Stock 4582 SYMBIO PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Market Closed - Japan Exchange
Other stock markets
 07:00:00 02/07/2024 BST 		5-day change 1st Jan Change
162 JPY 0.00% Intraday chart for SymBio Pharmaceuticals Limited -0.61% -34.41%
05-07 Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI
04-19 SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2022
Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022
Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4582 Stock
  4. News SymBio Pharmaceuticals Limited
  5. Other languages